We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Antibody-Drug Conjugates

News List

Block-buster Small Molecule Pharmaceuticals Approved by the NMPA in 2023 Yefenghong
March 06, 2024
According to data collated from the National Medical Products Administration (NMPA) official website, a total of more than 80 new drugs were granted inaugural approval within the domestic market.
LegoChem Biosciences, Iksuda collaborate to develop antibody-drug conjugates pharmaceutical-business-review
April 22, 2020
LegoChem Biosciences, based in Daejeon, South Korea, announced that it has entered a research collaboration and license agreement with Iksuda Therapeutics for the development of antibody-drug conjugates in oncology.
Glythera rebrands as Iksuda, pledging to solve ADC problems fiercebiotech
September 11, 2018
Despite their promise, antibody-drug conjugates (ADCs) have been tricky to bring to market, but the U.K. biotech formerly known as Glythera wants to change that.
Sutro Biopharma nets $85.4M to drive antibody-drug conjugates fiercebiotech
July 30, 2018
Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which includes a pair of antibody-drug conjugates (ADCs).
Jazz pays $75M for chance to buy into ImmunoGen ADCs fiercepharma
August 30, 2017
The deal with Jazz follows earlier agreements between ImmunoGen and Debiopharm and Sanofi.